← Back to Search

Predictive Analytics and Behavioral Nudges for Advanced Cancer

N/A
Waitlist Available
Led By Sandhya Mudumbi
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This trial seeks to improve palliative care access for cancer patients, which can improve symptom burden, quality of life, and survival.

Who is the study for?
This trial is for medical oncologists and advanced practice providers at Tennessee Oncology, treating patients with stage III or IV lung and non-colorectal GI cancers. Eligibility is determined using specific diagnosis codes, electronic health records (EHR), and manual screening.Check my eligibility
What is being tested?
The study tests if nudges in the EHR can increase palliative care use among advanced cancer patients. Practices are randomly assigned to either receive algorithm-based default referrals for palliative care or continue usual care without these prompts.See study design
What are the potential side effects?
Since this trial involves behavioral nudges rather than medications, there aren't direct physical side effects like those seen with drugs. However, changes in workflow or decision-making processes could occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Palliative Care Utilization in High-risk Patients
Secondary outcome measures
Palliative Care Utilization in Non-high Risk Patients

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports. Clinicians in the intervention arm will receive an EHR nudge with option to opt-out for palliative care referral for any eligible high-risk patient.
Group II: ControlActive Control1 Intervention
Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports. Clinicians will receive no further interventions beyond usual practice.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
104,528 Total Patients Enrolled
Tennessee Oncology, PLLCUNKNOWN
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,128 Total Patients Enrolled

Media Library

Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05590962 — N/A
Cancer Research Study Groups: Control, Intervention
Cancer Clinical Trial 2023: Intervention Highlights & Side Effects. Trial Name: NCT05590962 — N/A
Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05590962 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of participants for this medical research study?

"That is accurate. According to clinicaltrials.gov, this study initiated on November 9th 2022 and has been actively recruiting patients since then. 400 participants are sought out from a single medical centre."

Answered by AI

Is this experiment actively recruiting new participants?

"Affirmative, the trial is still recruiting. Clinicaltrials.gov records that it was launched on November 9th 2022 and last updated at the same time. 400 participants are needed from a single clinical site."

Answered by AI
~235 spots leftby Apr 2025